Technology
At the heart of our work at CompagOs, our core technology features Bon3OID™ in vitro models.
By combining 3D bioprinting, biomechanical stimulation, and micro-CT in a reproducible manner, we have developed a robust and scalable framework for drug development. In the future, we envision utilizing this framework not only to personalize treatments in fields with high unmet needs, such as bone metastasis and osteoporosis, but also to advance regenerative medicine by recreating bone tissue for patients with severe cancerous and traumatic conditions.
How We Create Bon3OID™ Models
01 From Cells to Organotypic Bone Models
We use 3D bioprinting to create human mesenchymal stem cell-laden hydrogel scaffolds, either from diseased or healthy donors.
02 Biomechanical Stimulation
These scaffolds are subjected to cyclic mechanical loading, stimulating cell-mediated mineralization and effectively mimicking human biology. Our bioreactors provide precise stimulation, similar to the mechanical load exerted to cells in bones during everyday activities like walking.
03 Introducing Cells
Our basic organotypic bone models consist of osteoblasts and osteocytes. Depending on specific research and clinical needs, we can introduce other types of cells, including osteoclasts and cancer cells.
How We Make a Difference
